Intrathecal liposomal cytarabine in relapsed or refractory infant and pediatric leukemias: The children’s hospital of philadelphia experience and review of the literature

Journal of Pediatric Hematology/Oncology

Volumn 32, Issue 8, 2010, Pages e349-e352

  Seif, Alix E ^a   Reilly, Anne F ^a   Rheingold, Susan R ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Acute leukemia; Infant; Intrathecal; Liposomal cytarabine; Pediatric

Indexed keywords

ACETAZOLAMIDE; ASPARAGINASE; ASPARAGINASE MACROGOL; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; GEMTUZUMAB; HYDROCORTISONE; LIPOSOMAL CYTARABINE; METHOTREXATE; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC ANTIMETABOLITE; LIPOSOME;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ARACHNOIDITIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CENTRAL NERVOUS SYSTEM LEUKEMIA; CHILD; CHILDHOOD LEUKEMIA; DRUG EFFICACY; DRUG MEGADOSE; FOLLOW UP; GRANULOCYTIC SARCOMA; HUMAN; INFANT; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKEMIC MENINGITIS; LUMBAR PUNCTURE; LUNG HEMORRHAGE; MALE; MULTIPLE ORGAN FAILURE; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PEDIATRIC HOSPITAL; PRIORITY JOURNAL; REVIEW; SCHOOL CHILD; SEPSIS; SKULL IRRADIATION; UNITED STATES; WHOLE BODY RADIATION; DRUG RESISTANCE; FEMALE; INTRASPINAL DRUG ADMINISTRATION; LEUKEMIA; PRESCHOOL CHILD; RECURRENT DISEASE;

ADOLESCENT; ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; CHILD, PRESCHOOL; CYTARABINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFANT; INJECTIONS, SPINAL; LEUKEMIA; LIPOSOMES; MALE; PHILADELPHIA; RECURRENCE;

EID: 78349253158     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181ec0c25     Document Type: Article

References (23)

1. Clarke M, Gaynon P, Hann I, et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol. 2003; 21: 1798-1809.
2. Bleyer WA, Poplack DG, Simon RM. " Concentration×time” methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood. 1978; 51: 835-842.
3. Chamberlain MC, Khatibi S, Kim JC, et al. Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101): a phase I study. Arch Neurol. 1993; 50: 261-264.
4. Kim S, Chatelut E, Kim JC, et al. Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol. 1993; 11: 2186-2193.
5. Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999; 5: 3394-3402.
6. Jaeckle KA, Batchelor T, O’Day SJ, et al. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol. 2002; 57: 231-239.
7. Bomgaars L, Geyer JR, Franklin J, et al. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol. 2004; 22: 3916-3921.
8. Benesch M, Siegler N, Hoff K, et al. Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study. Anticancer Drugs. 2009; 20: 794-799.
9. Benesch M, Sovinz P, Krammer B, et al. Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis. J Pediatr Hematol Oncol. 2007; 29: 222-226.
10. Jabbour E, O’Brien S, Kantarjian H, et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood. 2007; 109: 3214-3218.
11. Lassaletta A, Lopez-Ibor B, Mateos E, et al. Intrathecal liposomal cytarabine in children under 4 years with malignant brain tumors. J Neuro-Oncol. 2009; 95: 65-69.
12. Lassaletta A, Perez-Olleros P, Scaglione C, et al. Successful treatment of intracranial ependymoma with leptomeningeal spread with systemic chemotherapy and intrathecal liposomal cytarabine in a two-year-old child. J Neuro-Oncol. 2007; 83: 303-306.
13. Sancho JM, Ribera JM, Romero MJ, et al. Compassionate use of intrathecal depot liposomal cytarabine as treatment of central nervous system involvement in acute leukemia: report of 6 cases. Haematologica. 2006; 91: ECR02.
14. Hilgendorf I, Wolff D, Junghanss C, et al. Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation. Annals Hematol. 2008; 87: 1009-1012.
15. Parasole R, Menna G, Marra N, et al. Efficacy and safety of intrathecal liposomal cytarabine for the treatment of meningeal relapse in acute lymphoblastic leukemia: experience of two pediatric institutions. Leukemia and Lymphoma. 2008; 49: 1553-1559.
16. Seif A, Sutter J, Rheingold S. Secondary adrenal insufficiency in an infant after intrathecal triple chemotherapy. Pediatric Blood & Cancer. 2010; 55: 386-389.
17. Sancho JM, Deben G, Parker A, et al. Results of compassionate therapy with intrathecal depot liposomal cytarabine in acute myeloid leukemia meningeosis. Int J Hematol. 2007; 86: 33-36.
18. Sommer C, Lackner H, Benesch M, et al. Neuroophthalmological side effects following intrathecal administration of liposomal cytarabine for central nervous system prophylaxis in three adolescents with acute myeloid leukaemia. Annals Hematol. 2008; 87: 887-890.
19. Panosyan EHMD, Seibel NLMD, Martin-Aragon SP, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children’s Cancer Group Study CCG-1961. J Pediatric Hematol/Oncol. 2004; 26: 217-226.
20. Capizzi RL, Poole M, Cooper MR, et al. Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase. Blood. 1984; 63: 694-700.
21. Webb DKH, Wheatley K, Harrison G, et al. Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. Leukemia (08876924). 1999; 13: 25.
22. Johnston DL, Alonzo TA, Gerbing RB, et al. Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia. J Clin Oncol. 2005; 23: 9172-9178.
23. Roy A, Cargill A, Love S, et al. Outcome after first relapse in childhood acute lymphoblastic leukaemia-lessons from the United Kingdom R2 trial. Brit J Haematol. 2005; 130: 67-75.